Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

German Hepatitis C-Registry (DHC-R)

Trial Profile

German Hepatitis C-Registry (DHC-R)

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Boceprevir (Primary) ; Daclatasvir (Primary) ; Dasabuvir (Primary) ; Elbasvir/grazoprevir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Ombitasvir (Primary) ; Paritaprevir (Primary) ; Peginterferon alfa-2a (Primary) ; Peginterferon alfa-2b (Primary) ; Ribavirin (Primary) ; Simeprevir (Primary) ; Sofosbuvir (Primary) ; Telaprevir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Mar 2019 Results published in the Alimentary Pharmacology and Therapeutics
    • 13 Nov 2018 Interim results assessing the effectiveness of Elbasvir/Grazoprevir for the treatment of HCV GT1 infection by baseline viral load (n=531) presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
    • 14 Apr 2018 Interim results (n=531) assessing the impact of elbasvir/grazoprevir in GT1 cohort of patients, presented at The International Liver Congress 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top